Sex differences in nevirapine disposition in HIV-infected patients

AIDS

Volumn 17, Issue 16, 2003, Pages 2399-2400

  Regazzi, Mario ^a   Villani, Paola ^a   Seminari, Elena ^a   Ravasi, Giovanni ^a   Cusato, Maria ^a   Marubbi, Francesca ^a   Meneghetti, Grazia ^a   Maserati, Renato ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; STAVUDINE; ZIDOVUDINE;

ARTICLE; BODY COMPOSITION; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; FEMALE; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; SERODIAGNOSIS; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; STEADY STATE;

ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; SEX CHARACTERISTICS;

EID: 0742304500     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200311070-00018     Document Type: Article

References (8)

1. Burger DM, Siebers MC, Hugen PW, Aarnoutse RE, Hekster YA, Koopmans P, et al. Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men? J Acquir Immune Defic Syndr 2002, 29:101-107.
2. Currier JS, Spino C, Grimes J, Wofsy CB, Katzenstein DA, Hughes MD, et al. Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. J Acquir Immune Defic Syndr 2000, 24:316-324.
3. Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, et al. High-dose nevirapine: safety, pharmacokinetics, and viral antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995, 171:537-545.
4. Van Heeswijk RPG, Hoetelmans RMW, Meenhorst PL, Mulder JW, Beijnen JH. Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 1998, 713:395-399.
5. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001, 15:71-75.
6. Gatti G, Di Biagio A, Casazza R, DePascalis C, Bassetti M, Cruciano M, et al. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS 1999, 13:2083-2089.
7. Bersoff-Matcha S, Miller WC, Aberg JA, van der Horst C, Hamrick HJ, Powderly WG, et al. Sex differences in nevirapine rash. Clin Infect Dis 2001, 32:124-129.
8. Barreiro P, Soriano V, Casas E, Estrada V, Tellez MJ, Hoetelmans R, et al. Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. AIDS 2000, 14:2153-2157.